Search results
Results from the WOW.Com Content Network
Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults (about 2–4 ng/mL). [2]
A study was conducted where CA 242 serum levels were acquired from 34, 680 patients with 27 clinically defined diseases. The data acquired shows that patients with pancreatic cancer, cervical cancer and lymphoma had the highest levels of the CA 242 serum, which was followed by esophageal, colon and ovarian cancer. CA 242 can be shown to detect ...
n/a Ensembl ENSG00000181143 n/a UniProt Q8WXI7 n/a RefSeq (mRNA) NM_024690 NM_001401501 n/a RefSeq (protein) NP_078966 n/a Location (UCSC) Chr 19: 8.85 – 8.98 Mb n/a PubMed search n/a Wikidata View/Edit Human Mucin-16 (MUC-16) also known as Ovarian cancer-related tumor marker CA125 is a protein that in humans is encoded by the MUC16 gene. MUC-16 is a member of the mucin family glycoproteins ...
After cancer treatment ends patients will also usually have check-ups and scans arranged. Macmillan reminds us patients may need to recover from the emotional impacts, perhaps feeling anxious or ...
Women undergoing chemotherapy for breast cancer, who also began an aerobic exercise program at the same time, reported significant improvements in both cognitive function and quality of life.
According to Scope, 15 to 20 percent of people diagnosed with lung cancer are non-smokers. The diagnosis "is the result of a gene mutation that disproportionately affects those of Asian descent ...
Laboratory tumor lysis syndrome: abnormality in two or more of the following, occurring within three days before or seven days after chemotherapy. uric acid > 8 mg/dL or 25% increase; potassium > 6 meq/L or 25% increase; phosphate > 4.5 mg/dL or 25% increase; calcium < 7 mg/dL or 25% decrease
Guidelines from the American Society of Clinical Oncology discourage the use of CA19-9 as a screening test for cancer, particularly pancreatic cancer.The reason is that the test may be falsely normal (false negative) in many cases or abnormally elevated in people who have no cancer (false positive) in others.